Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 0.46 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.46 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ECE1 | P42892 | 2/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13313411 | 0.82 | ALDH1A1 (0.49) | MCL1BAK1ALDH1A1MEN1KMT2A | |
| SCHEMBL13348568 | 0.81 | TDP1 (0.40) | ALDH1A1LMNATDP1MEN1KMT2A | |
| SCHEMBL13313413 | 0.81 | MCL1 (0.43) | MCL1BAK1ALDH1A1LMNA | |
| SCHEMBL13313409 | 0.81 | MPO (0.43) | MCL1BAK1ALDH1A1LMNA | |
| SCHEMBL13313406 | 0.78 | CYP3A4 (0.46) | MCL1BAK1ALDH1A1MEN1KMT2A | |
| SCHEMBL13313412 | 0.78 | SQOR (0.43) | MCL1BAK1ALDH1A1LMNA | |
| SCHEMBL6588810 | 0.72 | PTGER1 (0.50) | MCL1P4HTMPTGER1ALDH1A1MEN1 | |
| SCHEMBL24983586 | 0.72 | P4HTM (0.55) | MCL1P4HTMPTGER1MEN1KMT2A | |
| SCHEMBL30892452 | 0.72 | P4HTM (0.55) | MCL1P4HTMPTGER1MEN1KMT2A | |
| SCHEMBL18348290 | 0.71 | MRGPRX4 (0.50) | MCL1P4HTMSRD5A1SRD5A2MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | ACHE, PSEN1, PSEN2 | MCL1 4710/4885BAK1 1460/4885P4HTM 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.